Symons Julian A. 4

What Happened Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics (ALGS), received a grant of 23,310 derivative shares (transaction code A) on March 9, 2026. The award was granted at $0.00 per share (no cash paid) and is reported as a derivative award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely under the 2-business-day rule).
• Award: 23,310 derivative shares granted at $0.00 per share (total reported value $0).
• Vesting: Footnote indicates 1/48th vests in equal monthly installments starting March 9, 2026; 100% vests on the fourth anniversary, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notes: This is a compensation/award grant (not a purchase or sale). No tax-withholding or disposition details were reported in the excerpt.

Context This award is a time-based equity grant that vests monthly over four years, a common retention/compensation structure for executives. Because it is an award (derivative) and not an open-market purchase, it does not represent an immediate cash investment by the insider nor an immediate sale of shares.